| 3.9299 -0.12 (-2.97%) | 12-15 15:59 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.84  |
1-year : | 5.66 |
| Resists | First : | 4.15 |
Second : | 4.84 |
| Pivot price | 3.71 |
|||
| Supports | First : | 3.51 |
Second : | 3.11 |
| MAs | MA(5) : | 3.99 |
MA(20) : | 3.65 |
| MA(100) : | 3.9 |
MA(250) : | 0 | |
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 89 |
D(3) : | 90.6 |
| RSI | RSI(14): 54.9 |
|||
| 52-week | High : | 5.36 | Low : | 1.61 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ LRMR ] has closed below upper band by 28.3%. Bollinger Bands are 3.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.15 - 4.18 | 4.18 - 4.2 |
| Low: | 3.85 - 3.87 | 3.87 - 3.89 |
| Close: | 3.89 - 3.93 | 3.93 - 3.97 |
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Fri, 14 Nov 2025
Here's Why We're Watching Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation - Yahoo Finance
Wed, 05 Nov 2025
Larimar Therapeutics Reports Third Quarter 2025 Financial Results - GlobeNewswire
Wed, 22 Oct 2025
Rosen Law Firm Encourages Larimar Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – LRMR - Business Wire
Wed, 08 Oct 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR - PR Newswire
Tue, 30 Sep 2025
Wedbush Maintains Larimar Therapeutics (LRMR) Outperform Recommendation - Nasdaq
Mon, 29 Sep 2025
100% of Friedreich's Ataxia Patients Hit Critical Protein Levels: Larimar's Drug Shows Disease-Modifying Potential - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 86 (M) |
| Shares Float | 37 (M) |
| Held by Insiders | 1 (%) |
| Held by Institutions | 100.1 (%) |
| Shares Short | 9,800 (K) |
| Shares Short P.Month | 9,100 (K) |
| EPS | -1.97 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.62 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -43 % |
| Return on Equity (ttm) | -78.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.63 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -96 (M) |
| Levered Free Cash Flow | -49 (M) |
| PE Ratio | -2.01 |
| PEG Ratio | 0 |
| Price to Book value | 2.42 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.49 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|